|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also summarize evidence for the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium glucose co-transporter-2 inhibitors (SGLT-2i) versus placebo on the risk of major cardiovascular events (MACE), heart failure (HF) and diabetic kidney disease (DKD).
|
31495989 |
2020 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is no compelling evidence of excess HF risk with the other DPP-4 inhibitors.
|
31816162 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-IV (DPP-IV) inhibitors reportedly have improved not only diabetes mellitus but also heart failure with systolic dysfunction in experimental models.
|
30880253 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The reasons for discrepancies with regard to heart failure risk with different dipeptidyl peptidase-4 inhibitors remain unclear, and further mechanistic studies are ongoing.
|
31741435 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
|
30794833 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversely, dipeptidyl peptidase 4 (DPP-4) inhibitors did not significantly affect atherosclerotic CVD end-points and some actually increased the risk of HF hospitalizations.
|
31442511 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The heart failure signal associated with DPP-4 inhibitor use is unclear with differing agents, demonstrating increased risk or maybe even protective effects.
|
31150300 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, SGLT2 inhibitors were associated with lower risk of hospitalization because of heart failure compared to both sulfonylureas and DPP-4 inhibitors, as well as lower risk of lower extremity amputation compared to sulfonylureas.
|
30039524 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this large Scandinavian cohort, SGLT2 inhibitor use compared with DPP4 inhibitor use was associated with reduced risk of heart failure and any cause death, but not with major cardiovascular events in the primary intention-to-treat analysis.
|
31467044 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The linagliptin study (CARMELINA) recruited people with renal disease as well as prior CV events and confirms the overall CV safety (and other safety) of the dipeptidylpeptidase-4 (DPP4) inhibitors, with no heart failure risk associated with this agent.
|
30607467 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.
|
31175007 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
DPP-4 inhibitors did not lower the risk of these outcomes when compared to placebo and were associated with higher risks of MACE, hospitalisation for HF, and renal composite outcome when compared to the other two drug classes.
|
31462224 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased rates of hospitalization for heart failure were seen with both saxagliptin and alogliptin, and this has led to a class warning for all dipeptidyl peptidase-4 inhibitors.
|
31127397 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiovascular-safety studies assessing glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 inhibitors have provided inconsistent data on the risk for developing heart failure.
|
30598343 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For DPP-4 inhibitors, uncertainties have been raised about their long-term effect on hospitalization for heart failure in light of the results of SAVOR-TIMI 53, although the findings of other DPP-4 inhibitor CVOTs in T2DM and data analyses have suggested these agents do not increase the occurrence of adverse CV outcomes.
|
30876392 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
CARMELINA also removed initial concerns for heart failure as a class-specific side-effect of dipeptidyl peptidase-4 inhibitors, as no signal for heart failure was found.
|
31018682 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The available research suggests that DPP-4 inhibitors cause sympathetic activation as a class effect and this may increase the risk of heart failure.
|
30318179 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such CVOTs have demonstrated that the effects of the new antidiabetic drugs on the mutual interactions between T2DM and HF may develop across different phases:Results of such trials can be summarized as: (a) all different classes of novel glucose-lowering drugs have good cardiovascular safety profile; (b) with respect to HF, DPP4 inhibitors might tend to increase risk; (c) sodium-glucose co-transporter 2 inhibitors (SGTLi), significantly reduce it; (d) glucagon-like peptide 1 receptor agonists (GLP1) tend to be neutral.
|
31479706 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Trials involving dipeptidyl peptidase-4 (DPP-4) inhibitors did not alter a composite MACE outcome comprising CV deaths, non-fatal myocardial infarction and non-fatal stroke; however, the possibility that some members of this class might incur a small increased risk or worsening of heart failure cannot be excluded.
|
30091169 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a meta-analysis of randomized controlled trials (RCTs) that evaluated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium glucose co-transporter-2 inhibitors (SGLT-2i) on heart failure (HF) risk in patients with type 2 diabetes (T2D).
|
31028667 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 inhibitors showed neutral effects and may increase risk of heart failure.
|
30767253 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on current evidence there are several clinical scenarios in which the use of sodium-glucose co-transporter-2 inhibitors would be justified for people with heart failure and atherosclerotic cardiovascular disease: (1) in people with a new diagnosis of Type 2 diabetes and for whom anti-hyperglycaemic management strategies are being considered; (2) in people with sub-optimal glycaemic control, regardless of baseline antihyperglycaemic therapy; and (3) in people with symptomatic heart failure (or other high-risk features such as recent hospitalization for heart failure), if glycaemic control is optimized and the individual is on a sulfonylurea or dipeptidyl peptidase-4 inhibitor; here, it may be reasonable to consider substituting one of those therapies for a sodium-glucose co-transporter-2 inhibitor.
|
31536660 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease.
|
30586723 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients.
|
30487758 |
2018 |